Efficacy and Safety of Percutaneous Nephrolithotomy in Patients with Chronic Kidney Disease: Outcomes from a Tertiary Care Center

医学 肾功能 肾脏疾病 经皮肾镜取石术 肌酐 围手术期 泌尿科 外科 前瞻性队列研究 肾病科 阶段(地层学) 内科学 经皮 生物 古生物学
作者
Harkirat Singh Talwar,Ankur Mittal,Vikas Kumar Panwar,Jyoti Mohan Tosh,Gurpremjit Singh,Rohit Ranjan,Rudra Prasad Ghorai,Sunil Kumar,Shivcharan Navriya,Arup Kumar Mandal
出处
期刊:Journal of Endourology [Mary Ann Liebert, Inc.]
卷期号:36 (5): 600-609 被引量:3
标识
DOI:10.1089/end.2021.0514
摘要

Background: The management of renal stone disease in the presence of chronic kidney disease (CKD) is a challenging scenario, both in terms of surgical safety and perioperative outcomes. The aim of the present study is to study the efficacy, safety, and outcomes of percutaneous nephrolithotomy (PCNL) in patients with CKD. Materials and Methods: A prospective study was conducted including adult patients with renal stone disease and a creatinine clearance of <90 mL/min (Stage 2 CKD or more) who underwent PCNL. Pre- and postoperative serum creatinine and glomerular filtration rates (GFRs) were compared. Patients were divided into CKD Stages 1 to 5 having creatinine clearance >90 mL/min, 60 to 90 mL/min, 30 to 60 mL/min, 15 to 30 mL/min, and <15 mL/min, respectively. Based on up migration or down migration of CKD stages, patients were classified as improved, deteriorated, or stable. Perioperative complications and outcomes were also compared. Results: A total of 185 patients with CKD Stage ≤2 underwent PCNL. The mean age of the patients was 43.24 ± 14.32 years. The mean preoperative estimated glomerular filtration rate (eGFR) was 62.88 ± 23.42 mL/min/1.73 m2. Preoperative CKD stage distribution was as follows: Stage 2 to 121 (65.4%), Stage 3 to 34 (18.4%), Stage 4 to 24 (13%), and Stage 5 to 6 (3.2%). On last follow-up of patients, the mean creatinine was 1.07 ± 0.65 mg/dL and the mean eGFR was 82.75 ± 31.22 mL/min/1.73 m2. The median change in creatinine and mean change in GFR were 0.23 (0.16-0.27) g/dL and 19.87 ± 19.77 mL/min/1.73 m2, respectively. Improvement in kidney function with a stage down migration was seen in 115 cases (62.2%), slight improvement with no change in stage in 69 cases (37.3%), and deterioration of CKD stage was present in one case (0.5%). Conclusion: PCNL is associated with favorable functional outcomes in CKD patients including severe CKD (Stages 4 and 5). Improvement or stabilization of CKD stage was seen in 99.5% of patients post-PCNL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
cc发布了新的文献求助10
刚刚
bobo发布了新的文献求助10
刚刚
1秒前
甜蜜冰珍完成签到,获得积分10
1秒前
Mao完成签到,获得积分10
2秒前
icecranberry完成签到,获得积分10
2秒前
乌鲁鲁星的北极兔完成签到 ,获得积分10
2秒前
Alien发布了新的文献求助10
2秒前
2秒前
lll发布了新的文献求助10
2秒前
yolo完成签到,获得积分10
3秒前
喵了个咪完成签到,获得积分10
3秒前
SPINE完成签到,获得积分20
3秒前
111完成签到,获得积分10
3秒前
田様的应助被hh采纳,获得30
3秒前
传奇3的应助被Slence采纳,获得10
4秒前
鹿邑完成签到,获得积分10
4秒前
Y_LH发布了新的文献求助10
5秒前
5秒前
Lizhuo完成签到,获得积分10
5秒前
高贵的尔烟完成签到 ,获得积分20
5秒前
打打的应助被知安采纳,获得10
5秒前
wangjqynu发布了新的文献求助10
6秒前
小小韩发布了新的文献求助10
6秒前
Yyyyy完成签到,获得积分10
6秒前
yy的应助被111采纳,获得10
6秒前
Mitte完成签到,获得积分10
6秒前
呆萌的冷玉完成签到,获得积分20
7秒前
淼淼苑完成签到,获得积分20
7秒前
无极微光的应助被铲铲大王采纳,获得20
7秒前
哈哈完成签到,获得积分10
7秒前
BAEKHYUNLUCKY发布了新的文献求助10
7秒前
无花果的应助被lll采纳,获得10
8秒前
平淡的惜芹完成签到,获得积分10
9秒前
LSD完成签到,获得积分10
9秒前
凶狠的白桃完成签到 ,获得积分10
9秒前
YY完成签到,获得积分10
10秒前
jjjwln完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Modern Artificial Intelligence 1000
Особенности технологий и методов информационно-психологических войн СССР с Великобританией и США в период 1939-1953 гг 1000
Das Matthäusevangelium: Kapitel 1:1–17 1000
IRTSD: Open-Source Data and Toolset for Electromagnetic Transient Analysis of Disturbances and IBR Control Malfunctions in Transmission Systems 1000
Entre Praga y Madrid : los contactos checoslovaco-españoles (1948-1977) 600
A REVIEW OF THE V-22 DYNAMICS VALIDATION PROGRAM 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8130443
求助须知:如何正确求助?哪些是违规求助? 9532748
关于积分的说明 21597652
捐赠科研通 7712347
什么是DOI,文献DOI怎么找? 3418123
关于科研通互助平台的介绍 2543854
邀请新用户注册赠送积分活动 2459422